Inactive Instrument

CEL-SCI Corporation Stock price Nyse

Equities

US1508375086

Pharmaceuticals

Sales 2024 * 130K Sales 2025 * 4.57M Capitalization 102M
Net income 2024 * -36M Net income 2025 * -25M EV / Sales 2024 * 683 x
Net cash position 2024 * 13.27M Net cash position 2025 * 15.33M EV / Sales 2025 * 19 x
P/E ratio 2024 *
-2.66 x
P/E ratio 2025 *
-3.82 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.81%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on CEL-SCI Corporation

Managers TitleAgeSince
Chief Executive Officer 66 86-12-31
Chief Tech/Sci/R&D Officer 83 09-10-31
Chief Tech/Sci/R&D Officer 66 93-09-30
Members of the board TitleAgeSince
Director/Board Member 67 17-12-18
Director/Board Member 79 02-07-31
Chief Executive Officer 66 86-12-31
More insiders
CEL-SCI Corporation is a clinical-stage biotechnology company. The Company is focused on activating the immune system to fight cancer and infectious diseases. The Company is engaged in research and developing the treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The Company is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company's Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock CEL-SCI Corporation
  4. Stock CEL-SCI Corporation - Nyse